STERIS plc

STERIS plc

STENYSE / NASDAQHealthcareLarge cap

$255.76+$1.00 (+0.4%)

Last close · Data as of Nov 20, 2026

Market cap
$20.7B
P/E
26.5x
EV / EBITDA
14.0x
Revenue
$5.9B
Net margin
13.2%
ROCE
11.5%

-0.5% over the last year

STERIS plc price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+13.6%
3M
+8.5%
6M
+18.4%
1Y
-0.5%
5Y
+9.5%

52-week range

Day change +$1.00 (+0.4%) from $255 to $256 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in STE, bought on each weekday since 2021.

News & filings

What STERIS filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthNet profit grew 94.1% a year over three years.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.

Read moreShow less

STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.

Sector
Healthcare
Shares outstanding
98.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$20.7B
P/E
26.5x
P/B
2.9x
EV / EBITDA
14.0x
EV / Sales
3.8x
P/S
3.5x
52-week high
$268.65
52-week low
$199.40

Profitability

Operating margin
18.6%
Net margin
13.2%
EBITDA margin
26.9%
ROE
10.9%
ROCE
11.5%
ROA
7.3%
Asset turnover
0.55

Growth

Revenue
$5.9B
Revenue growth, 1Y
8.7%
Revenue CAGR, 3Y
9.4%
Net profit growth, 1Y
27.3%
Free cash flow
$972.4M

Solvency

Current ratio
2.09
Debt / Equity
0.29
Debt / Assets
0.19
CFO / Net profit
1.71
Cash / Market cap
2.1%

Where the revenue went

Of every $100 of FY2026 revenue, $13 was left as net income.

STERIS plc income statement flow, FY2026
STERIS plc income statement flow, FY2026: flows
FromToAmount
RevenueCost of revenue$3.3B
RevenueGross profit$2.6B
Gross profitOperating expenses$1.5B
Gross profitOperating income$1.1B
Operating incomePretax income$1.0B
Operating incomeInterest and other expense$58.6M
Pretax incomeTax and other$265.0M
Pretax incomeNet income$782.3M

Revenue and net profit

Revenue grew 8.7% in FY2026; net profit is the dashed line.

STERIS plc revenue and net profit by fiscal year
STERIS plc revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$4.5B$107.0M
FY2024$5.1B$378.3M
FY2025$5.5B$614.7M
FY2026$5.9B$782.3M

Cash flows

FY2026: $1.3B from operations, $972.4M free after investment (dashed).

STERIS plc operating and free cash flow by fiscal year
STERIS plc operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023$756.9M$395.0M
FY2024$973.3M$613.0M
FY2025$1.1B$778.0M
FY2026$1.3B$972.4M

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$5.9B+8.7%1Y
EBITDA
$1.6B+17.4%1Y
Net profit
$782.3M+27.3%1Y
Cash from operations
$1.3B+16.8%1Y
Free cash flow
$972.4M+25.0%1Y
Revenue CAGR, 3Y
9.4%
Net profit CAGR, 3Y
94.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$5.9B$1.6B$782.3M$972.4M10.9%+8.7%+27.3%

Monthly returns

Month-by-month returns of STE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$10.7B
Liabilities$3.5B
Equity$7.2B
Retained earnings$3.0B
Minority interest$13.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; STE highlighted.

P/E against peers

STE trades at 26.5x earnings against a peer median of 21.9x (a 21% premium).

Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
STERIS plcSTEthis companyP/E ↑ premium$20.7B26.5x2.9x10.9%14.0x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
West Pharmaceutical Services, Inc.WST$22.4B45.4x7.1x15.5%28.4x
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Peer median—21.9x3.0x-6.9%13.2x

Year-to-date ROI

STE since 1 January, against earlier years.

Historical volatility

STE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

STERIS plc operating margin by fiscal year
STERIS plc operating margin by fiscal year
DateOperating margin
FY202317.5%
FY202416.8%
FY202517.6%
FY202618.6%
LineFY2026
Cost of revenueCost Of Revenue$3.3B
Gross profitGross Profit$2.6B
Operating expensesOperating Expense$1.5B
Research and developmentResearch And Development$112.9M
Selling, general and administrativeSelling General And Administration$1.4B
Total expensesTotal Expenses$4.8B
Pretax incomePretax Income$1.0B

Learn while you research

Academy chapters picked for STERIS plc and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →